Abstract
Purpose: The relations between Time Courses (TCs) of anti-TSH receptor auto-antibodies (TRAb) during Anti-Thyroid Drug (ATD) treatment and the outcome of Graves’ Disease (GD) were sought in relation to dental treatment.
Highlights
Anti-thyroid drugs (ATDs) have been employed for treatment of Graves’ disease (GD) worldwide
Remission of GD through ATD treatment is still unsatisfactory, eg., remission rates after ATD withdrawal reported in two recent meta-analyses are 48.7 % [1] and 57 % [2]
The levels of free thyroxine and hTRAb levels in the start of ATD are shown in figure 1
Summary
Anti-thyroid drugs (ATDs) have been employed for treatment of Graves’ disease (GD) worldwide. Remission of GD through ATD treatment is still unsatisfactory, eg., remission rates after ATD withdrawal reported in two recent meta-analyses are 48.7 % [1] and 57 % [2]. TSH receptor-specific treatment remains in investigational stage [3]. Means to improve remission rate with currently available ATD are worthy of being sought. Graves’ disease is known as an autoimmune disease caused by TSH-receptor-stimulating immunoglobulin [4,5]. Provided the production of TSH-receptorstimulating immunoglobulin antibodies is affected by comorbid disorder, the outcome of drug-treated GD might be improved by treating or eliminating comorbid disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
